A Phase 1 interventional study of VRON-0200-AdC6 and VRON-0200-AdC7 in Chronic Hepatitis B, sponsored by Virion Therapeutics. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Virion Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Hepatitis B, Chronic with a site in New Zealand — 8 open to participants now, 10 under way, none of them phase 3. Hepatitis B, Chronic · New Zealand.
Among the 82 studies in Hepatitis B, Chronic with a site in New Zealand, this one is the 63rd largest by enrollment of the 76 interventional ones that give a count, is one of 5 that started in 2023, is one of 38 in phase 1, and was the 71st registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →8 of the 82 studies in Hepatitis B, Chronic with a site in New Zealand are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in New Zealand, Australia, China and 4 more countries
Ages 18–65
IntegerBio · Sites in New Zealand, Hong Kong, Moldova and 1 more country
Ages 18–70 · Healthy volunteers
nChroma Bio · Sites in New Zealand, France, Hong Kong and 1 more country
Ages 18–64
Tune Therapeutics, Inc. · Sites in New Zealand, Hong Kong, Moldova
Ages 18–75
Precision BioSciences, Inc. · Sites in New Zealand, United States, France and 3 more countries
Ages 18–70
A study can be open while its sites in New Zealand have not opened yet or have stopped. Only those recruiting at a site in New Zealand →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 27 · Phase 3 9 · Phase 4 3
First in 2002; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 84 across the 76 interventional studies, 300 across the 6 observational. Of the 71 that completed or were terminated, 36 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 82 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Virion Therapeutics as lead sponsor.
Virion Therapeutics has 1 study filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies in Hepatitis B, Chronic with a site in New Zealand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06680232Precision BioSciences, Inc.Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B | 2026-12 |
| NCT06963710Aligos TherapeuticsA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | 2027-03 |
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
| NCT06661148Epigenic Therapeutics, IncStudy of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies in Hepatitis B, Chronic with a site in New Zealand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine, with documented HBV viral load suppression for at least 12 months.
Approximately 24 participants will be enrolled in Group 1 and randomized to Cohort 1a or Cohort 1b. Those assigned to Cohort 1a will receive a low dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 1b will receive a low dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination.
Group 2 will then enroll approximately 24 participants randomized to Cohort 2a or Cohort 2b. Those assigned to Cohort 2a will receive a high dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 2b will receive a high dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination.
Group 3 will enroll approximately 8 participants randomized into Cohort 3a or Cohort 3b. Cohort 3a will receive the high dose prime VRON-0200 vaccination of vector AdC7 on Day 1, followed by doses of VIR-2218 plus VIR-3434 on Days 28, 56, 84, 112, 140 and 168, and then a booster using a high dose VRON-0200 vaccination of vector AdC6 on Day 196. Cohort 3b will receive the same high dose prime VRON-0200 vaccination of vector AdC7 followed by 6 doses of VIR-2218 plus VIR-3434 at the same timepoints as Cohort 3a, but will not receive the booster dose on Day 196.
VRON-0200 vaccine doses will be administered by intramuscular (IM) injection. VIR-2218 and VIR-3434 will be administered subcutaneously.
All study participants will be followed for a total of 1 year post-prime vaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to Cohort 1a will receive a low dose prime vaccination of AdC7 vector on Day 1. They will receive a low dose boost vaccination of vector AdC6 on Day 91.
Biological: VRON-0200-AdC6 · Biological: VRON-0200-AdC7
Participants assigned to Cohort 1b will receive a low dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.
Biological: VRON-0200-AdC6
Participants assigned to Cohort 2a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive a high dose boost vaccination of AdC6 vector on Day 91.
Biological: VRON-0200-AdC6 · Biological: VRON-0200-AdC7
Participants assigned to Cohort 2b will receive a high dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.
Biological: VRON-0200-AdC6
Participants assigned to Cohort 3a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive VIR-2218 and VIR-3434 on Days 28, 56, 84, 112, 140, and 168. They will receive a high dose boost vaccination of AdC6 vector on Day 91.
Biological: VRON-0200-AdC6 · Biological: VRON-0200-AdC7 · Drug: VIR-2218 · Drug: VIR-3434
Participants assigned to Cohort 3a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive VIR-2218 and VIR-3434 on Days 28, 56, 84, 112, 140, and 168. They will not receive a boost vaccination.
Biological: VRON-0200-AdC7 · Drug: VIR-2218 · Drug: VIR-3434
VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
VIR-2218 given by subcutaneous injection
Also known as: elebsiran
VIR-3434 given by subcutaneous injection
Also known as: tobevibart, BRII-877
Treatment Emergent Adverse Events
Number and percent of participants with 1 or more treatment-emergent adverse events within 28 days after the last dose by cohort.
Time frame: 28 days
Grade 3 Adverse Events
Number and percent of participants with Grade 3 or higher local and/or systemic reactions within 28 days after the last dose by cohort.
Time frame: 28 days
Clinically Significant Changes in Lab Values
Number and percent of participants with clinically significant changes from pre-vaccination laboratory values within 28 days after the last dose by cohort.
Time frame: 28 days
Serious Adverse Events
Number and percent of participants with serious adverse events within 6 months after the last dose by cohort.
Time frame: 6 months
Medically Attended Adverse Events
Number and percent of participants with medically attended adverse events within 6 months after the last dose by cohort.
Time frame: 6 months
Adverse Events
Number and percentage of adverse events for all participants through Day 360.
Time frame: 360 days
T Cell Frequencies
Change from baseline in vaccine-induced CD8+ T cell frequencies in the blood.
Time frame: 360 days
Hepatitis B Virus DNA
Quantitative changes from baseline over time in HBV DNA
Time frame: 360 days
Hepatitis B Virus Pregenomic RNA
Quantitative changes from baseline over time in HBV pgRNA
Time frame: 360 days
Hepatitis B Surface Antigen
Quantitative changes from baseline over time in HBsAg
Time frame: 360 days
Ran from Sep 2023 to primary completion in Mar 2026, 30 months.
Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 30 months is above that.
Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elebsiran · Tobevibart